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What do we need to do to tackle antimicrobial resistance?
Infectious disease accounts for a substantial proportion 
of deaths worldwide. Continuing progress in the 
treatment of many infections is now threatened by 
the increasing numbers and widening distribution of 
pathogens resistant to antimicrobial (antibacterial, 
antiviral, antiparasitic, and antifungal) drugs. 
Until fairly recently, antimicrobial resistance was 
regarded as an issue mainly conﬁ ned to developed 
countries. Certainly, antimicrobial resistance is 
often widespread in high-income countries. Recent 
data suggest that at least 2 million Americans fall 
ill from antimicrobial-resistant pathogens every 
year, 23 000 of whom die from these infections.1 
Antimicrobial resistance also continues to increase 
in Europe, especially in Gram-negative bacterial 
pathogens;2 the excess mortality attributable to resistant 
hospital infections exceeds 25 000 deaths annually, and 
associated health-care costs and productivity losses total 
at least €1·5 billion each year.3 In addition to the direct 
eﬀ ects on mortality and morbidity and the economic 
burden, a loss of eﬀ ective antibiotics places at risk many 
of the procedures of modern medicine such as cancer 
chemotherapy, organ transplantation, and the care of 
premature babies.
Notwithstanding earlier assumptions, the threat of 
antimicrobial resistance is global. Data from around the 
world conﬁ rm that antimicrobial resistance, including 
multidrug resistance, is increasing in health-care 
settings and in the community.3 WHO is striving to 
articulate and address the issue3,4 and strategic initiatives 
in developing countries are attracting growing 
attention—eg, the roadmap constructed to tackle the 
global challenge from an Indian perspective5—but much 
more is needed. The crisis is exacerbated by a paucity of 
innovation in the development of new antibiotics, such 
that we are in danger of returning to a pre-antibiotic era.
Many of the national academies of science and medicine 
have a long history of interest in antimicrobial resistance, 
both in analysing the issues and proposing solutions. 
Recently, academies have started to work together 
to deliver stronger messages to policy makers—eg, in 
the European Union6 and the G8.7 This Comment is 
published to coincide with the launch of a statement8 by 
the global network of science academies represented by 
the InterAcademy Panel (IAP, representing academies 
of science) and the InterAcademy Medical Panel (IAMP, 
representing academies of medicine). IAP and IAMP 
share a commitment to strengthening the role of 
science in tackling societal priorities (including health), 
developing programmes for scientiﬁ c capacity building 
(including in health), supporting science education and 
communication, and encouraging the careers of young 
scientists. The academy networks provide an independent 
voice, free of vested political and commercial interests, 
and are able to draw upon the best science from all 
relevant disciplines and the experiences of the diﬀ erent 
contexts in which science has been applied.
The IAP-IAMP statement8 is a call for action, 
capitalising on previous work by member academies and 
others. In addressing recommendations to international 
and national policy makers, IAP and IAMP emphasise 
that antimicrobial resistance must receive much greater 
prominence in global strategic discussions. For example, 
although growing recognition of this threat to global 
health was apparent at the 66th World Health Assembly 
in May, 2013, the recent report9 by the UN high-level 
panel on the post-2015 development agenda omitted 
mention of antimicrobial resistance in the illustrative 
goals for health.
Panel: Global recommendations from the InterAcademy Panel and InterAcademy 
Medical Panel call for action to tackle antimicrobial resistance8
1 Develop, improve, and promote integrated surveillance systems for antimicrobial 
resistance in human and animal health sectors to provide the evidence base for action 
across sectors. The use of antibiotics in animal husbandry in many countries must be 
curtailed and other applications in agriculture re-examined.
2 Develop, improve, and implement information and education programmes about the 
rational and prudent use of anti-infective drugs, sharing evidence about what works 
to guide antibiotic stewardship eﬀ orts worldwide.
3 Produce education programmes for patients and the public on the prevention and 
management of infections.
4 Enable access for all to infection prevention and control programmes.
5 Recognise that migrant populations and medical tourists might be at particular risk, 
which has implications for screening of these and other vulnerable groups.
6 Encourage industry innovation and public–private collaborative research and 
development programmes for therapeutics, diagnostics, and vaccines.
7 Increase research capacity, including clinical research capacity, worldwide. The science 
agenda should incorporate fundamental biosciences research and social science 
research into the determinants of the origin and spread of drug resistance.
8 All these actions require new and improved commitment to, and structures for, a global 
partnership to tackle the research and innovation priorities, to share data, and to build 
and support sustained surveillance, stewardship, and infection control programmes.
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Preservation of the eﬀ ectiveness of existing anti-
microbial drugs and acceleration of the discovery and 
development of new drugs will both be crucial. To be 
successful, a comprehensive strategy based on sound 
science will need a much higher political and public 
visibility worldwide. A multidisciplinary, cross-sectoral 
approach needs to incorporate health, agriculture, 
development, economics, and other policy areas. 
In identifying the relevant priorities, the academies 
recommend coordinated action across a broad front; 
the common element in these diverse actions (panel) 
is the core importance of generating and using new 
knowledge.
Many of these actions, of course, have potentially 
wider value with respect to understanding 
communicable diseases and delivering improved 
health care. The present threat of antimicrobial 
resistance necessitates a global partnership to ensure 
sharing of good practice, provision of scientiﬁ c and 
technical assistance and the political commitment 
to underpin optimum surveillance, eﬀ ective and 
relevant research, accelerated innovation, and access to 
rational and prudent infectious disease management 
for all. Academies stand ready to play their part to 
clarify speciﬁ c options for action and to mobilise the 
biomedical community to participate. IAP and IAMP 
aim to continue to stimulate debate about solutions to 
diminish the present threat and avert worse problems 
as part of their expanding role in advising about how 
scientiﬁ c evidence can inform policy options for the 
post-2015 sustainable development challenges.10,11
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